LEVEL OF EVIDENCE: Therapeutic https://www.selleckchem.com/products/anlotinib-al3818.html Level I. See Instructions to Authors for a complete description of levels of evidence.”
“Background Parvovirus B19 (B19) disease is a rare cause of anemia in cancer patients and often goes unrecognized, causing delays in anticancer therapy.
Methods A retrospective review was carried out of the records of patients with multiple myeloma who underwent melphalan-based autologous stem cell transplantation (MEL-ASC ) and developed B19 infection (January 2009-December 2011). Cases were defined by the presence of
clinical and laboratory findings consistent with B19 disease in patients with repeatedly positive plasma quantitative polymerase chain reaction for parvovirus.
Results Six patients qualified as cases; 5 presented with trilineage cytopenias (chronic in 1) and 1 with anemia later progressing to pancytopenia. IVIG) resulted in clinical and hematologic response in all; however, 1 patient, whose white blood cell counts and serum hemoglobin levels improved, required splenectomy for persistent thrombocytopenia. All patients required additional IVIG for recurrent B19 disease. Although viral load at diagnosis did not correlate with
the severity of cytopenia, its decrease was associated with response during 17 of 20 evaluable episodes (P=0.02). Preemptive IVIG allowed the safe administration of mTOR inhibitor chemotherapy in 3 patients, including MEL-ASC in 1.
Conclusion Parvovirus B19 can cause severe disease in myeloma patients including ASC recipients. IVIG, although additional therapy was needed for recurrent disease. Most importantly, preemptive IVIG allowed for safe and timely administration of antineoplastic therapy in patients with ongoing B19 disease.”
“High costs and limited returns on investment have hampered progress in developing new diagnostic tests and treatments for tuberculosis
(TB). We need new biomarkers to develop assays that can rapidly, efficiently and reliably detect Mycobacterium tuberculosis infection and disease, identify drug resistance and expedite drug and vaccine development. This can only be accomplished through cross-disciplinary collaborations NVP-AUY922 cell line to facilitate access to human specimens. The Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health, the industry and academia experts came together in a June 2010 workshop to examine the field of TB diagnostic test development and biomarker discovery, identify areas of most urgent need and formulate strategies to address those needs.”
“BACKGROUND: The best treatment method for large tibial bone defects during revision knee replacement has not been established. The purpose of this study was to determine the initial results obtained with a unique reconstructive implant, the porous tantalum metaphyseal cone, designed as an alternative treatment for severe tibial bone loss following total knee arthroplasty.